Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Approval (2022) ZEPBOUND (Tirzepatide) Injection, for Subcutaneous Use: Initial U.S
EMA previously warned that off-label use of GLP-1 receptor agonists could worsen shortages, and that specific products are authorized for diabetes or weight management under defined conditions
Laboratory & Equipment: Product Display: Third-party Test Report: Packaging of our Retatrutide Lyophilized Powder: 10 Vials per Box (5mg/vial*10vials, 10mg/vial*10vials, 15mg/vial*10vials, 20mg/vial*10vials or 30mg/vial*10vials)
patent until 2032
US$ 27.82
US$ 23.61
US$ 21.29
US$ 28.69
US$ 24.86
US$ 27.54
US$ 23.79
US$ 25.07
US$ 26.13
US$ 21.76
US$ 21.18
